Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2,2-diphosphonoethyl)(dodecyl)dimethylphosphonium is a synthetic small molecule belonging to the bisphosphonate class of compounds[1][2]. Bisphosphonates are characterized by two phosphonate groups and are known for their ability to inhibit enzymes involved in isoprenoid biosynthesis. This compound has been studied as an inhibitor of geranylgeranyl diphosphate synthase (GGPPS), an enzyme critical for protein prenylation pathways that are important in cancer cell proliferation and survival[6]. The mechanism involves binding to the substrate and/or product sites of GGPPS, interfering with its function. While structurally related to other bisphosphonates used clinically for bone diseases, this compound is primarily experimental and has been investigated mainly in biochemical and structural studies as a potential anticancer agent targeting GGPPS[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2,2-diphosphonoethyl)(dodecyl)dimethylphosphonium.